Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6

Figure 1 Prospective studies evaluating a fixed 48-wk treatment using a standard dose of pegylated interferon and ribavirin in patients with hepatitis C genotype 4. SVR: Sustained viral response.

Figure 2 Studies comparing outcomes of 24 vs 48 wk of therapy with pegylated interferon and ribavirin in patients with hepatitis C virus genotype 6. ^aTreatment duration was tailored according to viral response at week 4: Patients with negative hepatitis C virus-RNA received 24 wk of treatment; the remainder received 48 wk. ns: Non-significant; nr: Not reported.